Agilent's GeneSpring Bioinformatics Solution integrated with GeneGo's MetaCore

GeneGo, Inc., a leading provider of databases, software and services in systems biology and chemistry, and Agilent Technologies, Inc., the world's premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications, announced today that they have integrated Agilent's GeneSpring Bioinformatics Solution with MetaCore.  

GeneSpring GX 11.5, released today, introduces a multi-omics microarray and mass-spectrometry based analysis suite to handle transcriptomics, genomics, metabolomics and proteomics data in one application. GeneSpring GX 11.5 includes a direct connection to the MetaCore pathway analysis engine that allows users to seamlessly upload expression data analyzed in GeneSpring for pathway analysis in MetaCore.  This connection is part of every expression workflow in GeneSpring, allowing automatic experiment creation and entity annotation in MetaCore.  

"We are very pleased to integrate GeneGo's MetaCore pathway analysis capabilities into GeneSpring's expression workflows," said Michael Janis, GeneSpring Product Manager at Agilent Technologies.  "Our users have access to industry-leading analysis and visualization tools within GeneSpring and the ability to combine statistical analysis in GeneSpring with MetaCore's strengths in pathway analysis will enable a deeper understanding of their research in a biological context."

"This will allow our joint customers to seamlessly work with omics data in the context of pathways," said Julie Bryant VP of business development.  "MetaCore can concurrently visualize multiple types of data and will be able to take advantage of this new functionality in GeneSpring which will be very helpful to our joint customers."

SOURCE GeneGo, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Evidence SARS-CoV-2 undergoes ADAR-mediated A-to-I RNA editing in human cells